viewOpyl Ltd

ShareRoot collaborates to support cancer research with MediaConsent

MediaConsent is one of ShareRoot’s three platforms.

gear wheel with word COLLABORATION on it
MediaConsent allows consumers and citizens to control their data and privacy

ShareRoot Ltd (ASX:SRO) has entered a collaboration that will see its MediaConsent platform used in a cancer clinical trial setting.

The collaboration is with Cancer Trials Australia (CTA) and the medical project is being led by The Social Science (TSS).

The MediaConsent Medical project now has three health or medical research related collaborators being St Vincent’s Hospital, Melbourne, Neuroscience Trials Australia, and CTA.

The shared goal with the MediaConsent clinical collaboration is to demonstrate how ShareRoot’s technology protects patient data and privacy whilst supporting the advancement of clinical research.

READ: ShareRoot Ltd attracts new substantial shareholder who has accumulated a 6.8% stake

Project leader Michelle Gallaher said: “The value of data in medical research is only growing as we find better ways to access and use data.”

“I’m really pleased to see MediaConsent applied to accelerating medical research and opening new ways for patients and carers to contribute to research by donating their data.”

CTA’s CEO Kurt Lackovic said: “We recognise the changing interest and value placed on real world data and real world evidence by both global regulators and the biopharma industry in shaping new treatments and products.

A platform like this could really democratise and transform clinical trials, enabling so many more people to participate in research, particularly from remote and regional areas or migrant populations that find it typically difficult to participate in clinical trials.”

MediaConsent able to be beneficial in healthcare sector

By collaborating with ShareRoot, clinical researchers can use MediaConsent to access a variety of consented real world data and evidence, in one platform.

Data that may be able to be integrated into the MediaConsent Medical platform may be derived from a number of sources which the patient would give consent for researchers and clinicians to use.

This includes data from social media and the internet, digital health wearables, private and public health records and statistics.

This puts patients in control of their data and ensures clinical researchers are compliant with the growing data privacy legislation and regulations around the world.

Quick facts: Opyl Ltd

Price: 0.145 AUD

Market: ASX
Market Cap: $4.29 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer...



Full interview: Opyl is new name of digital health track company ShareRoot

Opyl Limited (ASX:OPL) chief executive officer Michelle Gallaher updates Proactive on the renaming of the global digital health track company formerly known as ShareRoot Ltd (ASX:SRO). This heralds the company’s entry into the rapidly expanding global digital health and artificial...

on 9/12/19

2 min read